{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:37:12Z","timestamp":1773837432514,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>With the emergence of novel treatment products for haemophilia and an increasing focus on the benefits of pharmacokinetic driven individualized prophylaxis, robust national data with regard to current patterns of factor consumption and adherence are required.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To characterize current Australian practice with regard to use of prophylactic clotting factor infusions in patients with moderate or severe haemophilia A (<jats:styled-content style=\"fixed-case\">HA<\/jats:styled-content>) and haemophilia B (<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective, non\u2010interventional study utilizing Australian Bleeding Disorder Registry (<jats:styled-content style=\"fixed-case\">ABDR<\/jats:styled-content>) data collected over a 12\u00a0month period. Registered and consented patients with moderate or severe <jats:styled-content style=\"fixed-case\">HA<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content> without inhibitors were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 718 <jats:styled-content style=\"fixed-case\">HA<\/jats:styled-content> (551 severe, 167 moderate) and 166 <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content> (87 severe, 79 moderate) patients were included. Regular prophylaxis was prescribed in 453 patients (82%) with severe <jats:styled-content style=\"fixed-case\">HA<\/jats:styled-content>, 42 patients (25%) with moderate <jats:styled-content style=\"fixed-case\">HA<\/jats:styled-content>, 66 patients (75%) with severe <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content> and 11 patients (14%) with moderate <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>. Near universal prophylaxis was achieved in the paediatric subgroup. The mean weekly dose of factor <jats:styled-content style=\"fixed-case\">VIII<\/jats:styled-content> in severe <jats:styled-content style=\"fixed-case\">HA<\/jats:styled-content> was 84 international units\/kg\/wk (<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/kg\/wk) vs 71 <jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/kg\/wk of factor <jats:styled-content style=\"fixed-case\">IX<\/jats:styled-content> in severe <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>. Most patients on prophylaxis were treated \u22653\u00a0times\/wk (<jats:styled-content style=\"fixed-case\">HA<\/jats:styled-content>) or 2\u00a0times\/wk (<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>). Non\u2010adherence peaked in the 20\u201029\u00a0year age group. Older individuals on regular prophylaxis used more factor than was expected for their prescribed regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Prophylaxis rates in severe haemophilia are comparable with other developed nations. The benefit of a national registry is demonstrable. Furthermore research into the underlying reasons for non\u2010compliance in young adults with haemophilia is required.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.13375","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T12:20:45Z","timestamp":1514982045000},"page":"253-260","source":"Crossref","is-referenced-by-count":15,"title":["Australian multicentre study of current real\u2010world prophylaxis practice in severe and moderate haemophilia A and B"],"prefix":"10.1111","volume":"24","author":[{"given":"J. A.","family":"Mason","sequence":"first","affiliation":[{"name":"Australian Haemophilia Centre Directors Organisation (AHCDO)  Melbourne Vic. Australia"},{"name":"Queensland Haemophilia Centre Royal Brisbane and Women's Hospital  Brisbane QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Australian Haemophilia Centre Directors Organisation (AHCDO)  Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Tran","sequence":"additional","affiliation":[{"name":"Australian Haemophilia Centre Directors Organisation (AHCDO)  Melbourne Vic. Australia"},{"name":"Ronald Sawyers Haemophilia Centre The Alfred Hospital  Melbourne Vic. Australia"},{"name":"Australian Centre for Blood Diseases Monash University  Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rowell","sequence":"additional","affiliation":[{"name":"Australian Haemophilia Centre Directors Organisation (AHCDO)  Melbourne Vic. Australia"},{"name":"Queensland Haemophilia Centre Royal Brisbane and Women's Hospital  Brisbane QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9182-0447","authenticated-orcid":false,"given":"S.","family":"McRae","sequence":"additional","affiliation":[{"name":"Australian Haemophilia Centre Directors Organisation (AHCDO)  Melbourne Vic. Australia"},{"name":"Queensland Haemophilia Centre Royal Brisbane and Women's Hospital  Brisbane QLD Australia"},{"name":"Department of Haematology South Australia Pathology Royal Adelaide Hospital  Adelaide SA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04214.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03650.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH06-06-0307"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13298"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00546.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-2008"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12113"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-016-0096-y"},{"key":"e_1_2_10_11_1","unstructured":"Australian Bureau of Statistics.3101.0 \u2010 Australian Demographic Statistics March 2017.2016.http:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/0\/D56C4A3E41586764CA2581A70015893E?Opendocument. Accessed October 6 2017."},{"key":"e_1_2_10_12_1","first-page":"e251","article-title":"Compliance assessment in drug trials: has there been improvement in two decades?","volume":"12","author":"Jayaraman S","year":"2005","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01172.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13111"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0676-x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1997.00091.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12838"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000389"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02348.x"},{"key":"e_1_2_10_21_1","unstructured":"Australian Haemophilia Centre Directors Organisation.Guidelines for the management of haemophilia in Australia.2016.https:\/\/www.blood.gov.au\/system\/files\/HaemophiliaGuidelines-interactive-updated-260317v2.pdf. Accessed October 7 2017."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12878-015-0022-8"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01526.x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2001.00534.x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13360"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.13375","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.13375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:13:25Z","timestamp":1695539605000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.13375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/hae.13375"],"URL":"https:\/\/doi.org\/10.1111\/hae.13375","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]}}}